RYALTRIS™ is the only fixed-dose combination therapy that provides relief for the symptoms of SAR, both nasal and ocular in one easy-to-use nasal spray. The onset of action for nasal symptom relief occurs within 15 minutes of a patient taking the first dose.[1],[2],[3]

“Allergic rhinitis and allergic conjunctivitis are among the most common chronic diseases in the US today, affecting 60 million Americans each year,[4] yet approximately one in seven US adults have reported their nasal allergy symptoms are either poorly controlled or not controlled at all,[5] and ocular symptoms are reported to be as severe as nasal symptoms,”[6] said Leonard Bielory, M.D. Professor of Medicine, Allergy, Immunology and Ophthalmology at Hackensack Meridian School of Medicine. “By combining two of the most frequently prescribed medicines used to address both the nasal and ocular symptoms of seasonal allergic rhinitis into one, easy-to-use nasal spray, RYALTRIS™ provides an important new treatment option for patients suffering from this chronic condition affecting the nose and eyes.”

Uncontrolled seasonal allergic rhinitis is a serious condition that places a substantial burden on patients and society as whole. The symptoms of allergic rhinitis can lead to chronic complications including asthma, sinusitis, hearing impairment, and other allergy-related complications[7],[8],[9],[10] which can have a significant impact on patients’ quality of life.[11],[12],[13] There is an important need for new treatment options like RYALTRIS™ to help treat seasonal allergic rhinitis, as patients who do not experience adequate symptom relief may require therapy escalation to more costly and higher-risk treatments such as immunotherapy, biologics, and surgery.^{14,15,16,17,18}

“The launch of RYALTRIS™ is a significant step forward for Hikma in expanding our US nasal spray leadership into branded medicines and advancing our objective of growing our specialty business in the US,” said Brian Hoffmann, President of Hikma Generics. “Importantly, it will allow us to leverage our strong, existing specialty salesforce already calling on doctors within our specialty portfolio. We look forward to bringing this important new treatment option to the millions of US patients suffering from seasonal allergic rhinitis.”

“We are delighted to partner with Hikma for the launch of our novel drug RYALTRIS^TM in the United States, making it our first global branded specialty product to be marketed in the country. RYALTRIS^TM is a result of our consistent efforts to offer high-quality medicines that benefit patients around the world. Available in major markets across the globe, this launch is a major milestone for Glenmark and demonstrates our focus in strengthening our global respiratory leadership,” said Brendan O’Grady, Chief Executive Officer - Global Formulations Business, Glenmark Pharmaceuticals Ltd.

About RYALTRIS™

The efficacy and safety of RYALTRIS™ was established in a robust clinical studies program in over 4,000 patients with SAR. Twice-daily RYALTRIS™ provided statistically significant improvement in both nasal and ocular symptoms vs. placebo,^1,2,3 as well as statistically significant onset of action in nasal symptom relief vs. placebo at 10-15 minutes,^1,2,3 across three randomized, double-blind phase 3 studies (P<0.05). RYALTRIS™ also provided significant and clinically meaningful sustained improvements in nasal symptoms versus placebo over 52 weeks with no evidence of tachyphylaxis in patients with perennial allergic rhinitis (PAR).^1,2,3 RYALTRIS™ demonstrated a safety profile consistent with placebo, monotherapy, and comparator fixed-dose-combination treatment.^1,2,3

About Seasonal Allergic Rhinitis

Allergic rhinitis is one of the most common chronic diseases in the United States, affecting 60 million Americans annually.⁴ Season allergic rhinitis (SAR) occurs in a specific pollen season, and is an allergic reaction to pollen from trees, grasses, and weeds. According to the most recent CDC data, almost 20 million adults in the United Sates are affected by seasonal allergic rhinitis every year.[14] It is estimated to affect more than seven percent of adults aged 18 years and over in the US.¹³

[1] Patel P, et. al. Ann Allergy Asthma Immunol. 2019;122(2):160-166

[2] Gross GN, et. al. Ann Allergy Asthma Immunol. 2019;122(6):630-638

[3] Hampel FC, et. al. Allergy Asthma Proc. 2019;40(4):261-272

[4] Meltzer EO. Immunol Allergy Clin North Am. 2016;36(2):235-248

[5] Meltzer E, et al. Allergy Asthma Proc. 2012;33 (suppl 1):113-141.

[6] Bielory L, et al. Allergy Asthma Proc. 2014 ;35(3):211-8..

[7] National Institute for Health and Care Excellence. Complications allergic rhinitis. Updated April 29, 2019. Accessed January 2020.

[8] Settipane RA. Allergy Asthma Proc. 1999;20(4):209-213.

[9] Skoner, DP. J Allergy Clin Immunol. 2000;105(6 Pt 2) :S605-S609.

[10] Chirakalwasan N, et al. Asian Pac J Allergy Immunol. 2014;32(4):276-286.

[11] D’Alonzo, GE Jr. J Am Osteopath Assoc. 2002;102(6 suppl 2):S2-S6.

[12] Marple et al. Otolaryngol Head Neck Surg. 2007;136(suppl 6):S107-S124.

[13] Meltzer EO, et al. Allergy Asthma Proc. 2012;33(suppl 1):S113-S141.

[14] Seidman MD, et al. Otolaryngol Head Neck Surg. 2015;152(1S):S1-S43.

[15] Bhattacharyya N, et al. The Laryngoscope. 2019;129:1969–1975.

[16] ICER 2018 Final Report of Biologic Therapies for Treatment of Asthma Associated with Type 2 Inflammation. *2018 Wholesale Acquisition Costs x 1 year of dosing for allergic asthma (on-label indication). Use of biologics for SAR is off-label & dosing strategies are not established.

[17] Gevaert P, et al. J Allergy Clin Immunol. 2013;131:110-6.

[18] Wu A, et al. J Allergy Clin Immunol Pract. 2021;9:1107-17.